Functional PET imaging in cancer drug development

Area of Science:

• Oncology
• Medical Imaging
• Pharmacology

Background:

• Current cancer treatment monitoring relies on surrogate endpoints, necessitating advanced methods for evaluating novel therapies.
• Traditional methods like tumor size assessment and biopsies often fail to accurately reflect treatment efficacy.
• Functional imaging offers a promising alternative for real-time, in vivo assessment of therapeutic responses.

Purpose of the Study:

• To highlight the utility of Positron Emission Tomography (PET) as a functional imaging tool for monitoring cancer treatment response.
• To emphasize the advantages of PET, particularly F-18 fluorodeoxyglucose (FDG)-PET, over conventional structural imaging and invasive methods.
• To underscore the role of PET in evaluating novel anticancer agents and guiding drug development decisions.

Main Methods:

• Utilizing F-18 fluorodeoxyglucose (FDG)-PET to assess tumor glucose metabolism, a key indicator of treatment response.
• Employing PET to quantify biological processes targeted by anticancer therapies, including cellular metabolism and proliferation.
• Conducting PET pharmacokinetic studies to evaluate novel drug biodistribution and effects.

Main Results:

• FDG-PET reveals changes in tumor glucose metabolism that precede alterations in tumor size, indicating early drug effects.
• PET imaging provides a noninvasive, reproducible, and rapid assessment of treatment response and tumor viability.
• Functional PET readouts, such as changes in metabolism and perfusion, demonstrate whether drugs are achieving their intended biological effects.

Conclusions:

• PET imaging, especially FDG-PET, is a valuable tool for early and accurate prediction of cancer therapy response.
• Functional PET imaging is essential for assessing novel anticancer agents where size-based metrics are insufficient.
• PET facilitates efficient drug development by enabling rapid assessment of biodistribution and biological effects with smaller patient cohorts.